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A B S T R A C T
Background and objectives: Prevalence of overweight and obesity is high among colorectal cancer patients
upon diagnosis. Body weight may change substantially during treatment for colorectal cancer. In this study, we
describe changes in body weight in colorectal cancer patients during three periods: the period of surgery, during
adjuvant chemotherapy and during oncological follow-up; in addition, we assess which clinical/personal factors
were associated with weight change.
Subject/Methods: 485 stage II/III colorectal cancer patients diagnosed between 2007 and 2012 and treated
with surgery and adjuvant chemotherapy in three hospitals in the Netherlands were identiﬁed through the
Netherlands Cancer Registry. Data on changes in body weight were retrieved from medical records.
Results: Over the period of surgery, patients on average lost weight (mean −1.9 kg, SD 4.6 kg) (n=357). Weight
increased during chemotherapy (2.9 kg, SD 5.8 kg) (n=291) and increased during oncological follow-up (2.2 kg,
SD 6.6 kg) (n=242). Mean weight change over the total period was +2.0 kg (SD 6.8 kg) (n=283). Factors
univariately associated with weight gain were normal BMI (vs a BMI of 25–30), open surgery (vs laparoscopic
surgery) and Capecitabine monotherapy (vs Capecitabine plus Oxaliplatin). In a multivariate model, factors
were no longer associated with weight gain.
Conclusions: Body weight generally decreased during surgery and increased during and after chemotherapy.
During oncological follow-up, body weight generally was higher than upon diagnosis. Studies among other
patient groups suggest that weight changes may primarily aﬀect muscle mass, and may lead to e.g. sarcopenic
obesity. Future prospective studies are needed to explore this in colorectal cancer patients.
1. Introduction
Being overweight or obese are risk factors for colon and rectum
cancer [1–3]. As a result, prevalence of overweight and obesity are high
among colorectal cancer patients at diagnosis. Colorectal cancer
patients who are overweight or obese, may have a worse survival than
patients with normal body weight, although the literature on this is not
consistent [4,5]. Nevertheless, survival of colorectal cancer has im-
portantly improved over recent decades, which underlines the impor-
tance to study factors that can aﬀect long-term health and quality of life
of these survivors. One of the factors that may aﬀect health and quality
of life is body weight.
Chemotherapy has been associated with weight gain among color-
ectal cancer patients. An observational study within a randomized
controlled chemotherapy trial that included 1053 patients with stage
III colon cancer, suggested that body weight increased during adjuvant
treatment of colon cancer [6]. In the period from adjuvant chemother-
apy to 6 months after the end of chemotherapy the majority of patients
gained weight: 12% of the patients gained between 2 and 5 kg, while
64% of the patients gained at least 5 kg body weight [6]. Moreover, a
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cross-sectional study among long-term colorectal cancer survivors
showed that excess weight was associated with having received
chemotherapy [7].
Although body weight may increase during chemotherapy, studies
so far did not assess how body weight changed relative to body weight
at diagnosis, during the period of surgery and adjuvant chemotherapy
and in the following recovery period. The primary goal of our study was
therefore to describe changes in body weight during and after treat-
ment in stage II/III colorectal cancer patients undergoing surgery and
adjuvant chemotherapy. Secondary, we aimed to assess which personal
and/or clinical factors were associated with changes in body weight.
2. Methods
2.1. Patients
This study was performed among stage II/III colorectal cancer
patients diagnosed between 2007 and 2012 in one of three hospitals in
the Netherlands: Máxima Medical Centre in Eindhoven/Veldhoven,
Catharina Hospital in Eindhoven and hospital Gelderse Vallei in Ede.
Eligible patients were patients treated with both surgical resection and
adjuvant chemotherapy. The Netherlands Cancer Registry was used to
select eligible patients and to provide: date of incidence, comorbidities,
stage (II/III) and topography of the tumor (colon or rectum), type of
surgery (open, laparoscopic or laparoscopic with conversion: data were
available for patients treated in 2008 or later) and complications after
surgery (anastomotic leakage or abscess). Local review boards of the
three participating hospitals approved the study.
2.2. Data extraction
Data on body weight were retrieved from medical records. We
reviewed all medical ﬁles available from patients, e.g. chemotherapy
records, nursing records, records of follow-up visits, to search for
information on body weight. In addition, we extracted information
about date of body weight assessment, attained height, information
about treatment (radiotherapy: yes/no, type of chemotherapy:
Capecitabine+oxaliplatin, Capecitabine, 5-Fluorouracil+oxaliplatin
+leucovorin, other, amount of chemotherapy cycles, referral to a
dietician: yes/no, stoma: yes/no).
We aimed to retrieve information about changes in body weight
over three periods: during the period from diagnosis until start of
chemotherapy, during adjuvant chemotherapy and during oncological
follow-up. Body weight was not registered in the medical records at
every time point for all patients. For the ﬁrst period, we either used
body weight at diagnosis or at the day of surgery as begin weight and
body weight preceding the ﬁrst course of chemotherapy or body weight
shortly after surgery as end weight, depending on what was available.
For the second period, we used body weight preceding the ﬁrst course
of chemotherapy or body weight shortly after surgery as begin weight
and body weight shortly after chemotherapy or during the last course of
chemotherapy as end weight. For the third period, we used body weight
shortly after chemotherapy or during the last course of chemotherapy
as begin weight, and body weight during regular oncological follow-up
visits as end weight. Oncological follow-up visits were at least 6 months
after the end of chemotherapy.
2.3. Statistical analyses
In descriptive analyses, we calculated means and standard devia-
tions to describe changes in body weight over time.
We used univariate linear regression models to assess which clinical
or personal factors were associated with weight change from diagnosis
until at least six months after chemotherapy. Factors signiﬁcantly
associated with weight change were included in a multivariate model to
assess whether those factors were also independently associated with
weight change after adjusting for other factors. Statistical analyses were
carried out using Stata/SE 11.0.
Age and type of chemotherapy are strongly correlated as a result of
the Dutch oncological guidelines for the prescription of chemotherapy.
The Dutch oncological guidelines [8] suggest Capecitabine in combina-
tion with Oxaliplatin (or 5-Fluorouracil in combination with
Oxaliplatin) as the ﬁrst choice adjuvant treatment. The guidelines also
describe that the additional value of Oxaliplatin for elderly patients ( >
70yrs) may be limited. Thus Capecitabine monotherapy may be
considered for elderly patients. As age and type of chemotherapy are
strongly correlated, we studied weight change in patients below and
above the age of 70. In both age groups, we assessed whether type of
chemotherapy was associated with weight change.
3. Results
A number of 512 patients met our inclusion criteria. For 10
patients, we could not retrieve the medical records, for 17 patients,
we were not able to ﬁnd information on changes in body weight in the
medical records. Thus, our ﬁnal dataset consisted of 485 patients for
whom body weight information was available at diagnosis and at one or
more additional points in time.
We were able to retrieve information on change in body weight
during the period of surgery for 357 (74%) of the patients, the average
duration of the period was 69 days. We retrieved information on
change in body weight during the period of chemotherapy for 291
(60%) of the patients, the average duration of this period was 208 days.
We retrieved information on change in body weight during the period
after chemotherapy for 242 (50%) of patients, the average duration of
this period was 443 days. Over the total period from diagnosis until
oncological follow-up, information was available for 283 (58%) of the
patients, the average duration of this total period was 720 days.
Clinical characteristics were similar for patients for whom informa-
tion was available during the various periods in time, although the
number of patients of whom information could be retrieved varied
considerably, see Table 1.
Our study population of 485 patients consisted of slightly more men
(57%) than women, mean age of the patients was 64 yrs, see Table 1. A
percentage of 37% of the patients had a normal weight at diagnosis,
while 52% was overweight or obese (BMI > 25 kg/m2). Patients mostly
were diagnosed with stage III disease (87%), and with a tumor in the
colon (85%).
Mean body weight decreased over the period of surgery, (−1.9 ± SD
4.6 kg), increased during chemotherapy (2.9 ± 5.8 kg), and continued
to increase in the period of oncological follow-up (2.2 ± 6.6 kg), see
Fig. 1. There were large variations in changes in body weight between
patients, as can be seen from the large standard deviations. The mean
change in body weight in the period from start of chemotherapy until at
least six months after chemotherapy was +4.5 kg ( ± 7.4 kg). Mean
change in body weight in the total period from diagnosis until at least
six months after chemotherapy was +2.0 kg ( ± 6.8 kg).
Over this total period, weight change was less than 5% for 136
patients (48%). A number of 101 patients (36%) gained at least 5%
compared to weight at diagnosis: mean change in body weight in these
patients was 8.6 kg. A number of 46 patients (16%) lost at least 5% of
body weight: mean change in body weight was −8.1 kg.
Patients with normal BMI (18.5–25 kg/m2) generally gained more
weight in the total period from diagnosis until at least six months after
chemotherapy than patients with a higher BMI, although this was only
statistically signiﬁcant compared with the overweight category (BMI
25–30 kg/m2), see Table 2. Patients who were treated with open
surgery gained more weight over the total period than patients with
laparoscopic surgery. Patients treated with Capecitabine monotherapy
gained more weight than patients treated with a combination of
Capecitabine+Oxaliplatin. Gender and age were not associated with
weight change in our analyses, neither were the following clinical
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factors: stage or location of the tumor, having a stoma, treatment with
radiotherapy, complications after surgery, referral to a dietician,
number of chemotherapy cycles, and duration of time between two
assessments of body weight, see Table 2.
In a multivariate model, we included BMI at diagnosis, type of
surgery and type of chemotherapy simultaneously. In this multivariate
model, the betas for all characteristics attenuated and were no longer
statistically signiﬁcantly associated with weight change, see Table 2.
Among people below 70 yrs, 162 patients were treated with
Capecitabine+Oxaliplatin while only 17 patients received
Table 1
Clinical and personal characteristics of 485 colorectal cancer patients treated with surgery and adjuvant chemotherapy in three Dutch hospitals at diagnosis and of patients of whom
information on changes in body weight was available during various periods after diagnosis.
At diagnosis Period of surgery Period of chemo Period after chemo TOTAL PERIOD
Diagnosis until start
chemo (mean 69
days, SD 44 days)
Before chemo until
shortly after (mean
208 days, SD 130)
Shortly after chemo
until at least 6 mn
later (mean 443 days,
SD 407)
Diagnosis until at least 6
mn after chemo (mean
698 days, SD 426)
n 485 357 (74%) 291 (60%) 242 (50%) 283 (58%)
Gender, percentage of men 276 (57%) 198 (55%) 159 (55%) 131 (54%) 156 (55%)
Age, mean ( ± SD) 64 (10.6) 64 (10.6) 63 (10.7) 63 (10.9) 64 (10.8)
BMI at diagnosis kg/m2, mean ( ± SD) 26.3 (4.4) 26.3 (4.6) 26.4 (4.8) 26.3 (4.5) 26.4 (4.6)
BMI categories < 18.5 9 (2%) 8 (2%) 6 (2%) 5 (2%) 6 (2%)
18.5–25 178 (37%) 145 (41%) 109 (37%) 85 (35%) 110 (38%)
25–30 188 (39%) 146 (41%) 94 (32%) 86 (36%) 122 (43%)
30–35 44 (9%) 40 (11%) 34 (12%) 28 (12%) 30 (11%)
>35 21 (4%) 18 (5%) 14 (5%) 9 (4%) 15 (5%)
no information 45 (9%) 0 (0%) 34 (12%) 29 (12%) 0 (0%)
Stage II 61 (13%) 46 (13%) 34 (12%) 29 (12%) 39 (14%)
III 424 (87%) 311 (87%) 257 (88%) 213 (88%) 244 (86%)
Topography colon 410 (85%) 301 (84%) 245 (84%) 202 (83%) 241 (85%)
rectum 75 (15%) 56 (16%) 46 (16%) 40 (17%) 42 (15%)
Surgery laparoscopic 173 (36%) 132 (37%) 102 (35%) 82 (34%) 110 (39%)
conversion 49 (10%) 37 (10%) 28 (10%) 25 (10%) 32 (11%)
open 158 (33%) 121 (34%) 86 (30%) 65 (27%) 79 (28%)
no information 105 (22%) 67 (19%) 75 (26%) 70 (29%) 62 (22%)
Stoma yes 103 (21%) 82 (23%) 72 (25%) 57 (24%) 60 (21%)
no 324 (67%) 249 (70%) 186 (64%) 145 (60%) 190 (67%)
no information 58 (12%) 26 (7%) 33 (11%) 40 (17%) 33 (12%)
Radiotherapy yes 54 (11%) 42 (12%) 31 (11%) 24 (10%) 26 (9%)
no 431 (89%) 315 (88%) 260 (89%) 218 (90%) 257 (91%)
Complications surgery none 339 (70%) 257 (72%) 191 (66%) 150 (62%) 195 (69%)
anastomotic leakage
and/or abcess
42 (9%) 35 (10%) 33 (11%) 27 (11%) 28 (10%)
no information 104 (21%) 65 (18%) 67 (23%) 65 (27%) 60 (21%)
Counseling from dietician yes 230 (47%) 184 (52%) 155 (53%) 129 (53%) 146 (52%)
no 245 (51%) 165 (46%) 133 (46%) 110 (45%) 133 (47%)
no information 10 (2%) 8 (2%) 3 (1%) 3 (1%) 4 (1%)
Type of chemo Cap + ox 364 (75%) 260 (73%) 220 (76%) 185 (76%) 212 (75%)
Cap 93 (19%) 78 (22%) 54 (19%) 38 (16%) 50 (18%)
5-FU + ox + lv 13 (3%) 9 (3%) 8 (3%) 9 (4%) 11 (4%)
other 6 (1%) 4 (1%) 5 (2%) 4 (2%) 3 (1%)
no information 9 (2%) 6 (2%) 4 (1%) 6 (2%) 7 (2%)
No of chemo
cycles
1–4 54 (11%) 42 (12%) 31 (11%) 28 (12%) 35 (12%)
5–7 99 (20%) 69 (19%) 57 (20%) 53 (22%) 57 (20%)
8 or more 320 (66%) 238 (67%) 198 (68%) 154 (64%) 183 (65%)
no information 12 (2%) 8 (2%) 5 (2%) 7 (3%) 8 (3%)
Fig. 1. Mean number of days and mean weight change (+SD) during speciﬁc periods in colorectal cancer patients treated with surgery and adjuvant chemotherapy during and after
treatment.
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Capecitabine monotherapy. Weight change was 2.1 kg ( ± 6.2) over the
total period for patients treated with Capecitabine+Oxaliplatin and
2.6 kg ( ± 7.0) for patients treated with Capecitabine monotherapy.
Among patients above the age of 70, 50 patients were treated with
Capecitabine+Oxaliplatin, while 33 patients were treated with
Capecitabine monotherapy: among the Capecitabine+Oxaliplatin pa-
tients weight change over the total period from diagnosis until at least
six months after treatment was −0.1 kg ( ± 6.5), while in the
Capecitabine monotherapy group it was 4.5 kg ( ± 5.5).
4. Discussion
Our study among stage II/III colorectal cancer patients treated with
surgery and adjuvant chemotherapy showed that body weight changed
substantially from diagnosis until during oncological follow-up. In
general, patients lost weight during the period of surgery, gained
weight during chemotherapy and continued to gain weight after
chemotherapy. Over the total period from diagnosis until at least 6
months after treatment patients generally gained weight although
modestly (~2 kg). A substantial number of patients (36%) gained at
least 5% compared with their body weight at diagnosis: they gained on
average 8.6 kg.
Several factors were associated with weight change from diagnosis
until at least 6 months after chemotherapy: open surgery was asso-
ciated with more weight gain than laparoscopic surgery, while patients
on Capecitabine monotherapy gained more weight than patients on
Capecitabine+Oxaliplatin chemotherapy. In addition, patients with a
normal BMI gained more weight than patients who were overweight.
Nevertheless, these factors were only associated with weight gain in a
univariate regression model, not in a multivariate model suggesting
that the independent eﬀect of those factors on weight gain may only be
modest.
We were not able to retrieve pre-diagnostic body weights or pre-
diagnostic weight loss from medical records. Weight loss could be one
of the reasons for patients to see their doctor, leading to the diagnosis
of colorectal cancer. Thus, it is possible that patients catch up for this
pre-diagnostic weight loss in the period during and after treatment.
Possible, patients in the lower weight categories had lost more weight
Table 2
Mean weight change and univariate and multivariate regression coefficients within categories of clinical or personal characteristics during the total period from diagnosis until at least 6
months after chemotherapy in colorectal cancer patients with stage II or III disease treated with chemotherapy in three Dutch hospitals.
n Weight change (SD) univariate beta (95%CI) multivariate beta (95%CI)
Gender men 156 2.3 (6.5) REF
women 127 1.7 (7.0) −0.6 (−2.1, 1)
Age < 60 89 2.9 (7.9) REF
60–70 103 1.4 (5.9) −1.5 (−3.4, 0.4)
> 70 91 1.8 (6.3) −1.1 (−3.0, 0.9)
BMI at diagnosis (kg/m2) < 18.5 6 1.3 (6.3) −2.1 (−7.6, 3.4) 0.1 (−4.2, 4.4)
18.5–25 110 3.4 (6.7) REF REF
25–30 122 1.0 (6.0) −2.4 (−4.1, −0.6) −1.9 (−3.9, 0.1)
30–35 30 1.9 (8.0) −1.4 (−4.1, 1.3) −1.0 (−4.3, 2.2)
> 35 15 1.0(8.5) −2.2 (−5.9, 1.3) −3.2 (−7.7, 1.3)
Stage II 39 1.7 (5.0) REF
III 244 2.0 (7.0) 0.3 (−2.0, 1.7)
Topography colon 241 2.1(6.8) REF
rectum 42 1.6 (5.9) −0.5 (−2.7, 1.7)
Surgery laparoscopic 110 0.9 (6.7) REF REF
conversion 32 2.5 (7.7) 1.6 (−1.0, 4.2) 1.0 (−1.7, 3.8)
open 79 3.3 (6.0) 2.4 (0.4, 4.3) 2.0 (−0.0, 4.0)
Stoma yes 60 3.0 (7.3) 1.2 (−0.7, 3.2)
no 190 1.7 (6.6) REF
Radiotherapy yes 26 2.1 (5.7) 0.2 (−2.5, 2.9)
no 257 2.0 (6.8) REF
Complications after surgery none 195 1.8 (6.4) REF
Anastomotic leakage and/or abcess 28 2.3 (7.1) 0.5 (−2.1, 3.2)
Counseling from dietician yes 146 1.5 (7.1) −1 (−2.6, 0.6)
no 133 2.6 (6.3) REF
Type of chemo Cap + ox 212 1.5 (6.9) REF REF
Cap 50 3.9 (6.1) 2.3 (0.2, 4.4) 1.0 (−1.4, 3.4)
5-FU + ox + lv 11 2.8 (4.2) 1.3 (−2.8, 5.4) 0.9 (−3.4, 5.3)
other 3 4.1 (13.3) 2.6 (−5.1, 10.3) 1.8 (−6.1, 9.6)
No of chemo cycles 1–4 35 2.6 (5.9) REF
5–7 57 0.9 (7.4) −1.7 (−4.6, 1.1)
8 or more 183 2.2 (6.7) −0.4 (−2.8, 2.0)
Time between diagnosis and last known weight
6 months to 1 yr 56 0.9 (5.0) −0.9 (3.0, 1.2)
1–2 yrs 124 1.8 (6.4) REF
> 2yrs 103 2.9 (7.7) 1.1 (0.7, 2.9)
R.M. Winkels et al. Cancer Treatment and Research Communications 9 (2016) 111–115
114
before diagnosis and therefore were catching up more in the period
during and after treatment. There are data to suggest that heavier
patients lose more weight in the period of diagnosis than lower weight
patients [9]. However, as the medical records of the patients of our
study only rarely contained information about weight change before
diagnosis, we were not able to substantiate this possibility in this study.
In the Netherlands, patients are screened to detect (the risk of)
malnutrition upon admission into the hospital and at several moments
during the treatment. Nutritional advice is therefore mainly focussed
on prevention and/or treatment of unintentional weight loss. Our
results suggest that instead of only focussing on weight loss, it could be
important to monitor whether patients gain weight. Nevertheless,
future studies are needed to study how changes in body weight are
characterized in terms of body composition and how this impacts the
health of colorectal cancer survivors e.g. by using information from the
CT-scans [10] made upon diagnosis and follow-up [11].
Two things have to be taken into account in the interpretation of
our results. The ﬁrst is that information on body weight was not
registered at all points in time in the medical records. Possibly, body
weight was only registered in medical records for speciﬁc subgroups of
patients, thus leading to selection bias. However, we did not ﬁnd
indications for this, as the characteristics of patients of whom
information on body weight were available were similar for the various
time periods. Thus, we feel our ﬁndings are generalizable to all
colorectal cancer patients treated with surgery and adjuvant che-
motherapy.
The second consideration point is that assessment of body weight
was not standardized in the hospitals where we retrieved the informa-
tion: we did not have information on whether weight was self-reported
or measured on a calibrated scale based on a standard protocol. It is
well known that self-reported body weight can be prone to bias,
especially among persons who are of older age and among persons
with a high BMI [12–14]. However, as we do not have indications that
the method of assessment of body weight was diﬀerent for patients of
diﬀerent age or BMI groups, we assume that this did not introduce
diﬀerential errors and that our ﬁndings are valid.
Our ﬁndings may help to explain the ﬁndings of a recent review on
excess adiposity and survival in colorectal cancer [15]. One of the
ﬁndings of the review was that associations between adiposity and
survival may diﬀer according to when adiposity was assessed relative to
diagnosis. Our results show that body weight and BMI change
substantially during and after treatment, thus the association between
BMI and survival may indeed diﬀer based on whether diagnostic body
weight, or body weight later in time is considered in those analysis.
In conclusion, body weight varied substantially within and between
patients during and after treatment for colorectal cancer. This may
suggest that in clinical practice, not only weight loss, but also weight
gain should receive attention. Moreover, future studies should assess
whether there are changes in body composition and how they relate to
survival and quality of life.
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